Clinical Trial Detail

NCT ID NCT03126630
Title Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant pleural mesothelioma

Therapies

Pembrolizumab

Anetumab ravtansine + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.